NREP
NEW REPRESENTATIVE AT IB RECEIVED
09/26/2025
Back to search
Official data from USPTO
BEXIGNUS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
09/27/2025
Classification
Registered
Trademark type
Word
Nice classes
5
Filing date
08/12/2022
Registration date
04/30/2024
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/30/2024
Last transaction
09/27/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
09
Owner location
FI
Examiner
BLAZICH,JOAN MICHELE
Law office
N40
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Faron Pharmaceuticals Oy
Representatives
Mark E. Olds Muncy, Geissler, Olds & Lowe, P.C.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceuticals used for the prevention and treatment of cancerbone marrow dysfunction or suppressionshematological malignanciesimmunosystem related diseases and disordersdiseases of chronic infections in human tissue of an individual; Medical preparationspreparations for the prevention and treatment of cancerhematological malignanciesbone marrow dysfunction or suppressionsimmunosystem related diseases and disorders; Sanitary preparations for medical purposes; Pharmaceutical preparations and substances for the treatment of cancer; Tumor suppressing agents; Antineoplastics being preparations and pharmaceutical products for preventing and treating cancer and other immunosystem related diseases and disorders; Anti-cancer preparations; Compounds for treating cancerpharmaceutical products for the prevention and treatment of cancer; Antibodies for medical use to prevent and treat inflammation and cancer growth and spreadbone marrow dysfunction or suppressionshematological malignanciesimmunosystem related diseases and disorders; Biological preparations used for immune activation in the prevention and treatment of cancerimmunosystem related diseases and disordersbone marrow dysfunction or suppressionshematological malignancieschronic infections in human tissue of an individual; Adjuvants for medical purposes; Vaccine adjuvants; Anti-neoplastic preparations of chemical origin being pharmaceutical preparations for the prevention and treatment of cancerhematological malignanciesbone marrow dysfunction or suppressionsimmunosystem related diseases and disorderschronic infections; Anti-neoplastic preparations of microbial origin being pharmaceutical preparations for the prevention and treatment of cancerhematological malignanciesbone marrow dysfunction or suppressionsimmunosystem related diseases and disorderschronic infections; Antigenstumour antigens for medical diagnostic purposes and for anti-cancer preparations; Biological preparations for the treatment of cancer; Biopharmaceuticals for the treatment of cancer; Biotechnological preparations for medical usebiological preparations for the treatment of conditions with poor production of hematopoietic stem cells; Biotechnological preparations for medical usebiological preparations for the prevention and treatment of cancerhematological malignanciesbone marrow dysfunction or suppressionsimmunosystem related diseases and disorderschronic infections; Immunomodulatorspharmaceutical preparations for restoring and modifying the immune system; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations and substances for use in oncology; Pharmaceutical preparations for the prevention of disorders of the immune system; Serotherapeutic medicinespharmaceutical preparations used for immune activation in the treatment of cancer and in the treatment of diseases of chronic infections in human tissue of an individual; Pharmaceutical preparations for immunity adjustment; Pharmaceutical preparations for regulating the immune system; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for use in hematology
Publications
History of USPTO decisions and trademark events.
29 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
11/17/2024
FICS
FINAL DISPOSITION NOTICE SENT TO IB
10/26/2024
FIMP
FINAL DISPOSITION PROCESSED
10/26/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
07/30/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/30/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
04/30/2024
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
03/11/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/21/2024
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
02/21/2024
GPNX
NOTIFICATION PROCESSED BY IB
02/14/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/13/2024
PUBO
PUBLISHED FOR OPPOSITION
02/13/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/24/2024
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
01/24/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/24/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/05/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/29/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/29/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/29/2023
RFNT
REFUSAL PROCESSED BY IB
08/01/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/08/2023
RFRR
REFUSAL PROCESSED BY MPU
07/08/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/02/2023
CNRT
NON-FINAL ACTION WRITTEN
06/01/2023
DOCK
ASSIGNED TO EXAMINER
06/01/2023
MAFR
APPLICATION FILING RECEIPT MAILED
09/23/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/19/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
09/16/2022
Continuous trademark protection
Get notified about every new filing that threatens BEXIGNUS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.